Les anticorps monoclonaux en hématologie en 2009

Bonnet, Christophe; Beguin, Yves; De Prijck, Bernard; Witvrouw, Nancy; Hustinx, Roland; Fillet, Georges

Download

Article (Scientific journals)

Les anticorps monoclonaux en hématologie en 2009

Bonnet, Christophe; Beguin, Yves; De Prijck, Bernard et al.

2009 • In Revue Médicale de Liège, 64, p. 268-273

Peer reviewed

Permalink
https://hdl.handle.net/2268/25411

PubMed
19642457

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

252.pdf

Publisher postprint (426.49 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

NHL; CLL; Rituximab; 90Y ibritumomab tiuxetan; Alemtuzumab; LNH; LLC

Abstract :

[en] Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and offers superior response and survival rates. 90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of β irradiation. Given in monotherapy, it constitutes an interesting alternative therapy for follicular lymphomas in second relapse. Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in chronic lymphocytic leukemia resistant to classical chemotherapy.
[fr] Dirigé contre l'antigène CD20 présent à la surface des lymphocytes de phénotype B, le rituximab (MabThera) fait actuellement partie du traitement de première ligne des lymphomes non-Hodgkigniens folliculaires symptomatiques ainsi que des lymphomes diffus à grandes cellules B. Il permet une amélioration considérable des taux de réponse thérapeutique et de survie. Administré en monothérapie, l'90Y ibritumomab tiuxetan (Zevalin) combine la spécificité de l'anticorps monoclonal à l'encontre de l'antigène CD20 avec le pouvoir thérapeutique des radiations β et constitue une alternative thérapeutique pour les lymphomes folliculaires en deuxième rechute. L'alemtuzumab (MabCampath) reconnaît l'antigène CD52 et offre des résutlats encourageants lors du traitement de la leucémie lymphoïde chronique devenue résistante à la chimiothérapie classique.

Disciplines :

Hematology

Author, co-author :

Bonnet, Christophe ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

De Prijck, Bernard ; Université de Liège - ULiège > Hématologie clinique

Witvrouw, Nancy ; Université de Liège - ULiège > Médecine nucléaire

Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire

Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Language :

French

Title :

Les anticorps monoclonaux en hématologie en 2009

Alternative titles :

[en] Monoclonal antibodies in hematology in 2009

Publication date :

2009

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Pages :

268-273

Peer reviewed :

Peer reviewed

Available on ORBi :

since 12 October 2009

Statistics

Number of views

488 (17 by ULiège)

Number of downloads

476 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Robak T.- Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev Anticancer Ther, 2008, 8, 1033-1051.
Cheson BD, Leonard JP.- Monoclonal antibody thepy for B-cell non-Hodgkin's lymphoma. N Engl J Med, 2008, 359, 613-626.
Coiffier B.- Monoclonal antibodies in the treatment of malignant lymphomas. Adv Exp Med Biol, 2008, 610, 155-176.
Salles G, Mounier N, de Guibert S, et al.- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients : results of the GELA-GOELAMS FL2000 study. Blood, 2008, 112, 4824-4831.
Herold M, Haas A, Srock S, et al.- Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol, 2007, 25, 1986-1992.
Hiddemann W, Kneba M, Dreyling M, et al.- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005, 106, 3725-3732.
Marcus R, Imrie K, Solal-Celigny P, et al.- Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol, 2008, 26, 4579-4586.
Feugier P, van Hoof A, Sebban C, et al.- Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 2005, 23, 4117-4126.
Pfreundschuh M, Schubert J, Ziepert M, et al.- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol, 2008, 9, 105-116.
Habermann TM, Weller EA, Morrison VA, et al.- Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24, 3121-3127.
Pfreundschuh M, Trumper L, Osterborg A, et al.- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 2006, 7, 379-391.
Sehn LH, Donaldson J, Chhanabhai M, et al.- Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23, 5027-5033.
Sonneveld P, van Putten W, Biesma D, et al.- Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin's Lymphoma in Elderly Patients [abstract]. Blood, 2006, 108, #210.
Trneny M, Belada D, Vasova I, et al.- Rituximab Combination with Anthracyclin Based Chemotherapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups [abstract]. Blood, 2005, 106, #2444.
Haioun C, Mounier N, Emile JF, et al.- Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma [abstract]. Blood, 2005, 106, 200a.
Coiffier B, Lepretre S, Pedersen LM, et al.- Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia : a phase 1-2 study. Blood, 2008, 111, 1094-1100.
Zinzani PL, d'Amore F, Bombardieri E, et al.- Consensus conference : implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer, 2008, 44, 366-373.
Witzig TE, White CA, Wiseman GA, et al.- Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 1999, 17, 3793-3803.
Witzig TE, Gordon LI, Cabanillas F, et al.- Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 2002, 20, 2453-2463.
Wiseman GA, Gordon LI, Multani PS, et al.- Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood, 2002, 99, 4336-4342.
Witzig TE, Flinn IW, Gordon LI, et al.- Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 2002, 20, 3262-3269.
Morschhauser F, Illidge T, Huglo D, et al.- Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 2007, 110, 54-58.
Lin TS.- Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. Clin Lymphoma Myeloma, 2008, 8, Suppl 4, S137-S143.
Ferrajoli A, O'Brien SM, Cortes JE, et al.- Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer, 2003, 98, 773-778.
Moreton P, Kennedy B, Lucas G, et al.- Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol, 2005, 23, 2971-2979.
Keating MJ, Flinn I, Jain V, et al.- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 2002, 99, 3554-3561.
Rawstron AC, Kennedy B, Moreton P, et al.- Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood, 2004, 103, 2027-2031.